benzyl N-[(2S)-1-[(3-bromo-4,5-dihydro-1,2-oxazol-5-yl)methylamino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]carbamate
Modify Date: 2025-09-13 12:53:09
![benzyl N-[(2S)-1-[(3-bromo-4,5-dihydro-1,2-oxazol-5-yl)methylamino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]carbamate Structure](https://image.chemsrc.com/caspic/475/744198-19-4.png)
benzyl N-[(2S)-1-[(3-bromo-4,5-dihydro-1,2-oxazol-5-yl)methylamino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]carbamate structure
|
Common Name | benzyl N-[(2S)-1-[(3-bromo-4,5-dihydro-1,2-oxazol-5-yl)methylamino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]carbamate | ||
|---|---|---|---|---|
| CAS Number | 744198-19-4 | Molecular Weight | 476.32000 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C21H22BrN3O5 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of benzyl N-[(2S)-1-[(3-bromo-4,5-dihydro-1,2-oxazol-5-yl)methylamino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]carbamateKCC009, a transglutaminase 2 (TG2) inhibitor, induces p53-independent radiosensitization[1][2]. |
| Name | benzyl N-[(2S)-1-[(3-bromo-4,5-dihydro-1,2-oxazol-5-yl)methylamino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]carbamate |
|---|
| Description | KCC009, a transglutaminase 2 (TG2) inhibitor, induces p53-independent radiosensitization[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | The inhibition rates were 15.33±1.46 (%) for H1299/WT-p53 cells, and 14.31±1.90 (%) for H1299/M175H-p53 cells when cells were treated with KCC009 at concentration of 3.91 uM[1]. |
| References |
| Molecular Formula | C21H22BrN3O5 |
|---|---|
| Molecular Weight | 476.32000 |
| Exact Mass | 475.07400 |
| PSA | 116.23000 |
| LogP | 3.32350 |
| InChIKey | MRULUIQNANUWTK-ZVAWYAOSSA-N |
| SMILES | O=C(NC(Cc1ccc(O)cc1)C(=O)NCC1CC(Br)=NO1)OCc1ccccc1 |